Serum soluble tumour necrosis factor receptor type I concentrations independently predict prognosis in patients with breast cancerFUKSIEWICZ, Malgorzata; KOWALSKA, Maria; KOTOWICZ, Beata et al.Clinical chemistry and laboratory medicine. 2010, Vol 48, Num 10, pp 1481-1486, issn 1434-6621, 6 p.Article

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patientsFUKSIEWICZ, Malgorzata; KAMINSKA, Janina; KOTOWICZ, Beata et al.Clinical chemistry and laboratory medicine. 2006, Vol 44, Num 9, pp 1092-1097, issn 1434-6621, 6 p.Article

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival studyLEYLAND-JONES, Brian; SEMIGLAZOV, Vladimir; BIAKHOV, Mikhail et al.Journal of clinical oncology. 2005, Vol 23, Num 25, pp 5960-5972, issn 0732-183X, 13 p.Article

Phase III study of N, N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19REYNO, Leonard; SEYMOUR, Lesley; PIENKOWSKI, Tadeusz et al.Journal of clinical oncology. 2004, Vol 22, Num 2, pp 269-276, issn 0732-183X, 8 p.Article

Alteration of Topoisomerase II―Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based ChemotherapyPRESS, Michael F; SAUTER, Guido; ROBERT, Nicholas et al.Journal of clinical oncology. 2011, Vol 29, Num 7, pp 859-867, issn 0732-183X, 9 p.Article

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanesJONES, Alison; O'BRIEN, Mary; SOMMER, Harald et al.Cancer chemotherapy and pharmacology. 2010, Vol 65, Num 4, pp 755-763, issn 0344-5704, 9 p.Article

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer : Update of study BIG 1-98COATES, Alan S; KESHAVIAH, Aparna; LDNG, Istvdn et al.Journal of clinical oncology. 2007, Vol 25, Num 5, pp 486-492, issn 0732-183X, 7 p.Article

Adjuvant Trastuzumab in HER2-Positive Breast CancerSLAMON, Dennis; EIERMANN, Wolfgang; PINTER, Tamas et al.The New England journal of medicine. 2011, Vol 365, Num 14, pp 1273-1283, issn 0028-4793, 11 p.Article

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic RegimensVALERO, Vicente; FORBES, John; FUMOLEAU, Pierre et al.Journal of clinical oncology. 2011, Vol 29, Num 2, pp 149-156, issn 0732-183X, 8 p.Article

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialDAVIES, Christina; HONGCHAO PAN; BRADBURY, Joan et al.Lancet (British edition). 2013, Vol 381, Num 9869, pp 805-816, issn 0140-6736, 12 p.Article

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer PatientsHURVITZ, Sara A; BETTING, David J; DAMARAJU, Sambasivarao et al.Clinical cancer research (Print). 2012, Vol 18, Num 12, pp 3478-3486, issn 1078-0432, 9 p.Article

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analysesCAMERON, David; CASEY, Michelle; CHAN, Arlene et al.Breast cancer research and treatment. 2008, Vol 112, Num 3, pp 533-543, issn 0167-6806, 11 p.Article

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 StudyCOLLEONI, Marco; GIOBBIE-HURDER, Anita; CHIRGWIN, Jacquie et al.Journal of clinical oncology. 2011, Vol 29, Num 9, pp 1117-1124, issn 0732-183X, 8 p.Article

Adjuvant docetaxel for node-positive breast cancerMARTIN, Miguel; PIENKOWSKI, Tadeusz; GUEVIN, Raymond et al.The New England journal of medicine. 2005, Vol 352, Num 22, pp 2302-2313, issn 0028-4793, 12 p.Article

Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapyMARKOWICZ, Sergiusz; WALEWSKI, Jan; ZAJDA, Katarzyna et al.Cytokines, cellular & molecular therapy. 2002, Vol 7, Num 1, pp 15-24, issn 1368-4736Article

Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer : Final results of a randomized phase III multicenter trialJASSEM, Jacek; PIENKOWSKI, Tadeusz; MUNIER, Stephane et al.Journal of clinical oncology. 2001, Vol 19, Num 6, pp 1707-1715, issn 0732-183XArticle

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerBASELGA, Jose; CORTES, Javier; CLARK, Emma et al.The New England journal of medicine. 2012, Vol 366, Num 2, pp 109-119, issn 0028-4793, 11 p.Article

Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 TrialEIERMANN, Wolfgang; PIENKOWSKI, Tadeusz; PRESS, Michael et al.Journal of clinical oncology. 2011, Vol 29, Num 29, pp 3877-3884, issn 0732-183X, 8 p.Article

Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samplesZACZEK, Anna; MARKIEWICZ, Aleksandra; JASKIEWICZ, Janusz et al.Clinical biochemistry. 2010, Vol 43, Num 10-11, pp 891-898, issn 0009-9120, 8 p.Article

A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast CancerJAGIELLO-GRUSZFELD, Agnieszka; TJULANDIN, Sergei; DOBROVOLSKAYA, Natalya et al.Oncology. 2010, Vol 79, Num 1-2, pp 129-135, issn 0030-2414, 7 p.Article

Lapatinib plus capecitabine for HER2-positive advanced breast cancerGEYER, Charles E; FORSTER, John; SKARLOS, Dimosthenis et al.The New England journal of medicine. 2006, Vol 355, Num 26, pp 2733-2743, issn 0028-4793, 11 p.Article

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced Breast CancerPEGRAM, Mark D; PIENKOWSKI, Tadeusz; RIVA, Alessandro et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 10, pp 759-769, issn 0027-8874, 11 p.Article